Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 13
ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 15
ANI Pharma Acquires Generic ANDA Product Portfolio from IDT Australia for USD2.7 Million 16
ANI Pharma Acquires Four NDA’s from AstraZeneca 17
ANI Pharma Acquires Inderal XL from Cranford Pharma for USD20 Million 18
ANI Pharma Acquires InnoPran XL from Holmdel Pharma for USD31 Million 19
ANI Pharma Acquires Inderal LA Assets from Cranford Pharma 20
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 21
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 22
ANI Pharma Acquires ANDA from Teva Pharma 23
ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 24
ANI Pharma Acquires Lithobid from Noven Therapeutics for USD12 Million 25
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 26
Partnerships 27
ANI Pharma Enters into Distribution Agreement with Aspen 27
ANI Pharma Enters into Agreement with H2-Pharma 28
ANI Pharma Enters into Agreement with IDT Australia 29
ANI Pharma Extends Co-Development Agreement With Sterling Pharma 30
ANI Pharma Enters Into Development Agreement With Sterling Pharma 31
Ani Pharma Enters Into Co-Development Agreement With Sofgen Pharma For Oral Soft Gel Prescription Product 32
Merger 33
BioSante Pharma And Ani Pharma Complete Merger 33
Licensing Agreements 35
ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 35
Ani Pharma Enters Into Licensing Agreement With Sofgen Pharma For Oral Soft Gel Product 36
Equity Offering 37
WellSpring Pharma Services Invests USD3 Million in IDT Australia 37
ANI Pharma Completes Public Offering Of Shares For US$50 Million 38
Debt Offering 39
ANI Pharma Raises USD143.8 Million in Public Offering of 3% Notes Due 2019 39
ANI Pharma Raises USD287.5 Million in Public Offering of 2.125% Notes Due 2023 41
Acquisition 42
ANI Pharma Acquires WellSpring Pharma from Sentinel Capital for USD18 Million 42
ANI Pharmaceuticals Inc – Key Competitors 43
ANI Pharmaceuticals Inc – Key Employees 44
ANI Pharmaceuticals Inc – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Recent Developments 46
Financial Announcements 46
Aug 07, 2018: ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2018 Results and Updates Guidance 46
May 08, 2018: ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance 51
Feb 27, 2018: ANI Pharmaceuticals Reports Record Full Year Results, Reports Fourth Quarter 2017 Results, and Provides 2018 Guidance 54
Nov 02, 2017: ANI Pharmaceuticals Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year Guidance 58
Aug 03, 2017: ANI Pharmaceuticals Reports Record Second Quarter and Year-To-Date 2017 Results and Reaffirms Guidance 61
May 04, 2017: ANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2017 Highlights and Reaffirms Guidance 63
Mar 02, 2017: ANI Pharmaceuticals Reports Full Year 2016 Results and Fourth Quarter Results and Provides 2017 Guidance 65
Corporate Communications 68
Jun 05, 2018: ANI Pharmaceuticals Appoints Three New Board of Directors 68
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ANI Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ANI Pharma to Acquire Generic Products from Amneal Pharma and Impax Labs 13
ANI Pharma to Acquire Manufacturing Equipment from Amneal Pharma and Impax Labs 15
ANI Pharma Acquires Generic ANDA Product Portfolio from IDT Australia for USD2.7 Million 16
ANI Pharma Acquires Four NDA’s from AstraZeneca 17
ANI Pharma Acquires Inderal XL from Cranford Pharma for USD20 Million 18
ANI Pharma Acquires InnoPran XL from Holmdel Pharma for USD31 Million 19
ANI Pharma Acquires Inderal LA Assets from Cranford Pharma 20
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 21
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 22
ANI Pharma Acquires ANDA from Teva Pharma 23
ANI Pharma Acquires Vancocin Capsules and Vancomycin Assets from Shire for USD11 Million 24
ANI Pharma Acquires Lithobid from Noven Therapeutics for USD12 Million 25
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 26
ANI Pharma Enters into Distribution Agreement with Aspen 27
ANI Pharma Enters into Agreement with H2-Pharma 28
ANI Pharma Enters into Agreement with IDT Australia 29
ANI Pharma Extends Co-Development Agreement With Sterling Pharma 30
ANI Pharma Enters Into Development Agreement With Sterling Pharma 31
Ani Pharma Enters Into Co-Development Agreement With Sofgen Pharma For Oral Soft Gel Prescription Product 32
BioSante Pharma And Ani Pharma Complete Merger 33
ANI Pharma Enters into Licensing Agreement with Dexcel Pharma 35
Ani Pharma Enters Into Licensing Agreement With Sofgen Pharma For Oral Soft Gel Product 36
WellSpring Pharma Services Invests USD3 Million in IDT Australia 37
ANI Pharma Completes Public Offering Of Shares For US$50 Million 38
ANI Pharma Raises USD143.8 Million in Public Offering of 3% Notes Due 2019 39
ANI Pharma Raises USD287.5 Million in Public Offering of 2.125% Notes Due 2023 41
ANI Pharma Acquires WellSpring Pharma from Sentinel Capital for USD18 Million 42
ANI Pharmaceuticals Inc, Key Competitors 43
ANI Pharmaceuticals Inc, Key Employees 44
ANI Pharmaceuticals Inc, Other Locations 45
ANI Pharmaceuticals Inc, Subsidiaries 45
List of Figures
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ANI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9